Publication:
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.

Simple item page
dc.contributor.authorBüyükkapu, Bay
dc.contributor.authorKEBUDI, R
dc.contributor.authorGORGUN, O
dc.contributor.authorZÜLFIKAR, B
dc.contributor.authorDARENDELILER, E
dc.contributor.authorÇakır, FATMA BETÜL
dc.contributor.institutionauthorÇAKIR, FATMA BETÜL
dc.date.accessioned2019-10-05T22:01:09Z
dc.date.available2019-10-05T22:01:09Z
dc.date.issued2018-08-06
dc.identifier10.1016/j.kisu.2017.10.007
dc.identifier.citationBüyükkapu B., KEBUDI R., GORGUN O., ZÜLFIKAR B., DARENDELILER E., Çakır F. B. , -Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.-, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018
dc.identifier.doi10.1177/1078155218790798
dc.identifier.pubmed30080131
dc.identifier.urihttps://hdl.handle.net/20.500.12645/8698
dc.identifier.wosWOS:000476565600008
dc.language.isoen
dc.titleVincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
dc.typeArticle
dspace.entity.typePublication
local.article.journalnameKIDNEY INTERNATIONAL SUPPLEMENTS
local.avesis.idd8938939-92c4-4740-b649-f8db6e2c3afc
local.avesis.response8574
local.indexed.atPubMed
local.indexed.atWOS
local.publication.isinternational1
relation.isAuthorOfPublication4b01ee0e-c087-44d4-9581-4d73032d078e
relation.isAuthorOfPublication.latestForDiscovery4b01ee0e-c087-44d4-9581-4d73032d078e

Files

Collections

Yayınlar - Eserler
Tıp Fakültesi